Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HL-008
- Development stage
- Phase 1
- Lead developer
- Huili Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
HL-008 is a small molecule antioxidant and free radical scavenger being developed by Huili Pharmaceutical (Suzhou) Co., Ltd. It is currently in Phase 1 clinical trials in China for the treatment of schizophrenia, where it is administered as an injection. The drug exerts neuroprotective effects by alleviating oxidative stress and inflammation, reducing glial cell activation, and inhibiting apoptosis in brain tissue. Preclinical studies have also demonstrated its potential in treating ischemia-reperfusion injury, showing significant reductions in cerebral infarction volume and improvements in neurological scores.
Beyond the preview
Go deeper on HL-008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HL-008.